Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 1,500 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini sold 1,500 shares of the business’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $30.99, for a total value of $46,485.00. Following the completion of the sale, the general counsel now owns 54,374 shares in the company, valued at $1,685,050.26. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Jeff Cislini also recently made the following trade(s):

• On Monday, March 18th, Jeff Cislini sold 1,252 shares of Revolution Medicines stock. The shares were sold at an average price of $31.58, for a total value of $39,538.16.
• On Monday, January 22nd, Jeff Cislini sold 1,500 shares of Revolution Medicines stock. The stock was sold at an average price of $27.00, for a total value of $40,500.00.

Revolution Medicines Price Performance

RVMD stock traded up $0.51 during trading on Thursday, hitting $32.23. 997,438 shares of the stock traded hands, compared to its average volume of 1,368,769. Revolution Medicines, Inc. has a 1 year low of $15.44 and a 1 year high of $35.60. The firm’s 50 day moving average is $29.90 and its two-hundred day moving average is $27.16. The stock has a market cap of $5.31 billion, a price-to-earnings ratio of -8.58 and a beta of 1.53.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Monday, February 26th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.29). Revolution Medicines had a negative net margin of 1,003.36% and a negative return on equity of 38.39%. The firm had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $1.20 million. During the same period last year, the company posted ($0.63) earnings per share. The business’s revenue for the quarter was down 95.2% compared to the same quarter last year. As a group, analysts anticipate that Revolution Medicines, Inc. will post -3.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Revolution Medicines

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its stake in Revolution Medicines by 40.8% during the 4th quarter. Wellington Management Group LLP now owns 14,882,086 shares of the company’s stock valued at $426,818,000 after acquiring an additional 4,309,611 shares during the period. Vanguard Group Inc. lifted its stake in shares of Revolution Medicines by 51.8% in the 4th quarter. Vanguard Group Inc. now owns 14,634,391 shares of the company’s stock worth $419,714,000 after purchasing an additional 4,990,800 shares during the period. BlackRock Inc. lifted its stake in shares of Revolution Medicines by 10.6% in the 2nd quarter. BlackRock Inc. now owns 8,257,616 shares of the company’s stock worth $220,891,000 after purchasing an additional 791,842 shares during the period. Nextech Invest Ltd. lifted its stake in shares of Revolution Medicines by 30.1% in the 4th quarter. Nextech Invest Ltd. now owns 6,296,740 shares of the company’s stock worth $180,591,000 after purchasing an additional 1,457,211 shares during the period. Finally, BVF Inc. IL lifted its stake in shares of Revolution Medicines by 26.2% in the 2nd quarter. BVF Inc. IL now owns 6,255,588 shares of the company’s stock worth $167,337,000 after purchasing an additional 1,300,000 shares during the period. Institutional investors own 94.34% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on RVMD shares. Bank of America raised Revolution Medicines from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $31.00 to $34.00 in a report on Friday, January 5th. Piper Sandler assumed coverage on Revolution Medicines in a research note on Monday, March 11th. They issued an “overweight” rating and a $43.00 target price for the company. Wedbush upped their target price on Revolution Medicines from $41.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. Raymond James upped their target price on Revolution Medicines from $30.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 16th. Finally, UBS Group assumed coverage on Revolution Medicines in a research note on Wednesday, December 20th. They issued a “buy” rating and a $40.00 target price for the company. Ten analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $38.80.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.